| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Rocket Pharmaceuticals Inc (NASDAQ: RCKT)
RCKT Technical Analysis
5
| As on 20th Aug 2025 RCKT STOCK Price closed @ 3.75 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 19.27 & Strong Sell for SHORT-TERM with Stoploss of 24.94 we also expect STOCK to react on Following IMPORTANT LEVELS. |
RCKTSTOCK Price
| Open | 3.83 | Change | Price | % |
| High | 4.10 | 1 Day | 0.84 | 28.87 |
| Low | 3.14 | 1 Week | 0.83 | 28.42 |
| Close | 3.75 | 1 Month | 0.55 | 17.19 |
| Volume | 59831314 | 1 Year | -23.80 | -86.39 |
| 52 Week High 28.71 | 52 Week Low 2.33 | ||||
NASDAQ USA Most Active Stocks
| AMRS | 0.14 | 100.00% |
| OPEN | 3.22 | -11.05% |
| NVDA | 175.40 | -0.14% |
| INTC | 23.54 | -6.99% |
| LMDX | 0.02 | 0.00% |
| AKTS | 0.04 | 0.00% |
| SOFI | 22.52 | -1.01% |
| TSLA | 323.90 | -1.64% |
| LCID | 2.09 | -1.88% |
| LILM | 0.05 | 0.00% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| RCKT Daily Charts |
RCKT Intraday Charts |
Whats New @ Bazaartrend |
RCKT Free Analysis |
|
|
RCKT Important Levels Intraday
| RESISTANCE | 5.60 |
| RESISTANCE | 5.01 |
| RESISTANCE | 4.64 |
| RESISTANCE | 4.27 |
| SUPPORT | 3.23 |
| SUPPORT | 2.86 |
| SUPPORT | 2.49 |
| SUPPORT | 1.90 |
RCKT Forecast August 2025
| 4th UP Forecast | 13.1 |
| 3rd UP Forecast | 10.1 |
| 2nd UP Forecast | 8.25 |
| 1st UP Forecast | 6.39 |
| 1st DOWN Forecast | 1.11 |
| 2nd DOWN Forecast | -0.75 |
| 3rd DOWN Forecast | -2.6 |
| 4th DOWN Forecast | -5.6 |
RCKT Weekly Forecast
| 4th UP Forecast | 8.53 |
| 3rd UP Forecast | 7.00 |
| 2nd UP Forecast | 6.05 |
| 1st UP Forecast | 5.10 |
| 1st DOWN Forecast | 2.40 |
| 2nd DOWN Forecast | 1.45 |
| 3rd DOWN Forecast | 0.50 |
| 4th DOWN Forecast | -1.03 |
RCKT Forecast2025
| 4th UP Forecast | 54.89 |
| 3rd UP Forecast | 38.49 |
| 2nd UP Forecast | 28.35 |
| 1st UP Forecast | 18.21 |
| 1st DOWN Forecast | -10.71 |
| 2nd DOWN Forecast | -20.85 |
| 3rd DOWN Forecast | -30.99 |
| 4th DOWN Forecast | -47.39 |
Rocket Pharmaceuticals Inc ( NASDAQ USA Symbol : RCKT )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
RCKT Business Profile
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has four clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO Inc. The company also has a research and collaboration agreement with Lund University; and strategic collaboration agreement with Stanford University School of Medicine. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey. Address: 9 Cedarbrook Drive, Cranbury, NJ, United States, 08512
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service